Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US8816242098

SecurityTEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
InstitutionNEXT Financial Group, Inc
Latest Disclosed Ownership12,126 shares
Latest Disclosed Value $ 97,000
NEXT Financial Group, Inc reports 14.40% increase in ownership of TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)

On February 15, 2022 - NEXT Financial Group, Inc filed a 13F-HR form disclosing ownership of 12,126 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) (US:TEVA) valued at $97,129 USD as of December 31, 2021. The entity filed a previous 13F-HR on October 15, 2021 disclosing 10,600 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock). This represents a change in shares of 14.40% during the quarter. The current value of the position is $414,588 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2022-02-15 2021-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 12,126 1,526 14.40 97 -6.73 0.0064
2021-10-15 2021-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 10,600 164 1.57 104 0.97 0.0081
2021-07-13 2021-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 10,436 -372 -3.44 103 -17.60 0.0082
2021-04-16 2021-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 10,808 3,312 44.18 125 73.61 0.0111
2021-02-05 2020-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 7,496 -7,414 -49.73 72 -46.27 0.0069
2020-10-22 2020-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 14,910 14,910 134 0.0144
2020-07-23 2020-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 0 -6,824 -100.00 0 -100.00
2020-04-27 2020-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 6,824 2,969 77.02 61 60.53 0.0079
2020-01-21 2019-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 3,855 -546 -12.41 38 26.67 0.0039
2019-10-17 2019-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 4,401 125 2.92 30 -23.08 0.0033
2019-07-16 2019-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 4,276 3,394 384.81 39 178.57 0.0042
2019-07-16 2019-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 882 -2,764 -75.81 14 -75.00 0.0035
2019-02-11 2018-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 3,646 2,479 212.43 56 124.00 0.0116
2018-10-09 2018-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 1,167 1,167 25 0.0116
2018-01-16 2017-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 0 -9,877 -100.00 0 -100.00
2017-11-08 2017-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 9,877 -697 -6.59 148 -57.83 0.0412
2017-07-12 2017-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 10,574 6,350 150.33 351 163.91 0.0858
2017-05-08 2017-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 4,224 -4,297 -50.43 133 -56.96 0.0370
2017-02-02 2016-12-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 8,521 1,383 19.38 309 -5.79 0.0543
2016-11-01 2016-09-30 13F TEVA PHARMACEUTICAL INDS ADR 881624209 7,138 2,401 50.69 328 38.40 0.0592
2016-07-07 2016-06-30 13F TEVA PHARMACEUTICAL INDS ADR 881624209 4,737 575 13.82 237 6.76 0.0752
2016-04-20 2016-03-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 4,162 1,175 39.34 222 13.27 0.0783
2016-02-02 2015-12-31 13F/A-1 TEVA PHARMACEUTICAL INDS ADR 881624209 2,987 -475 -13.72 196 0.51 0.0730
2016-02-02 2015-12-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 2,987 196
2015-10-20 2015-09-30 13F TEVA PHARMACEUTICAL INDS ADR 881624209 3,462 0 0.00 195 -4.41 0.0698
2015-07-29 2015-06-30 13F TEVA PHARMACEUTICAL INDS ADR 881624209 3,462 -200 -5.46 204 -10.53 0.0703
2015-04-15 2015-03-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 3,662 150 4.27 228 12.87 0.0732
2015-02-10 2014-12-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 3,512 -2,328 -39.86 202 -35.67 0.0671
2015-02-10 2014-09-30 13F/A-1 TEVA PHARMACEUTICAL INDS ADR 881624209 5,840 5,754 6,690.70 314 7,750.00 0.0625
2014-10-23 2014-09-30 13F TEVA PHARMACEUTICAL INDUSTRIES LTD ADR COM 881624209 5,840 314
2014-08-14 2014-06-30 13F TEVA PHARMACEUTICALINDUSTRIES LTD ADRISIN#US8816242098 LTD ADR 881624209 86 86 4 0.0021
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.